• 1  Carruthers JD, Carruthers JA. Treatment of glabellar frown lines with C. botulinim‐A toxin. J Dermatol Surg Oncol 1992;18:17–22. Cross Ref link Pubmed link
  • 2  Keen M, Blitzer A, Aviv J, et al. Botulinum toxin A for hyperkinetic facial lines: results of a double‐blind, placebo‐controlled study. Plast Reconstr Surg 1994;94:94–9. Cross Ref link Pubmed link
  • 3  Lowe NJ, Maxwell A, Harper H. Botulinum A exotoxin for glabellar folds: a double‐blind, placebo‐controlled study with an electromyographic injection technique. J Am Acad Dermatol 1996;35:569–72. Cross Ref link Pubmed link
  • 4  Carruthers JD, Lowe NJ, Menter MA, et al., for the BOTOX Glabellar Lines I Study Group. A multicenter, double‐blind, randomized, placebo‐controlled study of the efficacy and safety of Botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol 2002;46:840–9. Cross Ref link Pubmed link
  • 5  Carruthers JD, Lowe NJ, Menter MA, et al., for the BOTOX Glabellar Lines II Study Group. Double‐blind, placebo‐controlled study of the safety and efficacy of Botulinum toxin type A for patients with glabellar lines. Plast Reconstr Surg 2003;112:1089–98. Cross Ref link Pubmed link
  • 6  Ascher B, Zakine B, Kestemont P, et al. A multicenter, randomized, double‐blind, placebo‐controlled study of efficacy and safety of 3 doses of Botulinum toxin A in the treatment of glabellar lines. J Am Acad Dermatol 2004;51:223–33. Cross Ref link Pubmed link
  • 7  Lowe P, Patnaik R, Lowe N. Comparison of two formulations of Botulinum type A for the treatment of glabellar lines: a double‐blind randomized study. J Am Acad Dermatol 2006;55:975–80. Cross Ref link Pubmed link
  • 8  Naumann M, Jost W, Toyka KV. Treatment of disorders of the autonomic nervous system with botulinum Toxin A. Arch Neurol 1999;56:914–16. Cross Ref link Pubmed link
  • 9  Naumann M, Lowe NJ. Botulinum toxin type A in treatment of bilateral primary axillary hyperhydrosis; randomised parallel group, double blind, placebo controlled trial. BMJ 2001;323:1–4. Cross Ref link Pubmed link
  • 10  Erbgurth F, Nauman M. Historical aspect of botulinum toxin; Justinus Kerner (1786–1862) and the “sausage poison”. J Hist Neurol 2000;9:218–20. Cross Ref link
  • 11  Scott AB. Development of Botulinum toxin therapy. Dermatol Clin 2004;22:131–3. Cross Ref link Pubmed link
  • 12  Scott AB, Rosenbaum A, Collins CC. Pharmacologic weakening of extraocular muscles. Invest Ophthalmol 1973;12:924–7. Pubmed link
  • 13  Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology 1980;87:1044–9. Cross Ref link Pubmed link
  • 14  Naumann M, Jost W, Toyka KV, Moore P. History and current application of botulinum toxin from poison to remedy. In: Moore P, Naumann M, eds. Handbook of Botulinum Toxin Treatment, 2nd edn, Chapter .3–8. Oxford: Blackwell Science, 2003.
  • 15  Blasi J, Chapman ER, Link E, et al. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP. Nature 1993;365;160–3. Cross Ref link Pubmed link
  • 16  Schiavo G, Banfanti F, Poulain B, et al. Tatarus and botulinum B neurotoxins block neuromuscular transmitter release by proteoytic cleavage of synaptobrevin. Nature 1992;359:832–5. Cross Ref link Pubmed link
  • 17  Lowe NJ, Shah A, Lowe PL. Dosing, efficacy, safety and computerized photography of botulinum toxins. J Cosmet Laser Therapy 2010;12.2:106–11. Cross Ref link
  • 18  Sattler G, Callander MJ, Grablowitz D, et al. Non inferiority of Incobotulimun toxin‐A, compared with another botulinum. Toxin type A. J Dermatol Surg 2010;36:2146–54. Cross Ref link
  • 19  Maas C. One Botulinum Toxin slightly better than another for crow's feet. Arch Facial Plast Surg 2011;Dec 19. Pubmed link
  • 20  Lowe NJ. When and how to combine treatments. In: Lowe NJ, et al., ed. Textbook of Facial Rejuvenation, Chapter . London: Martin Dunitz/Taylor & Francis, 2002:322–5. Cross Ref link
  • 21  Lowe NJ, Ascher B, Heckmann M, et al., for the Botox Facial Aesthetics Study Team. Double‐blind, randomized, placebo‐controlled, dose‐response study of the safety and efficacy of Botulinum toxin type A in subjects with crow's feet. Dermatol Surg 2005;31:257–62. Cross Ref link Pubmed link
  • 22  Yamauchi P, Lowe NJ, Lask GL. Botulinum toxin plus Erb Yag Laser for periorbital lines. J Cosmet Laser Ther 2004;6.3:145–8. Cross Ref link
  • 23  Carruthers J, Carruthers A, Maberly D. Deep resting glabellar rhytides respond to BTX‐A and Hylan BD. Dermatol Surg 2003;29:539–44. Pubmed link
  • 24  Brandt F. Efficacy and safety evaluation of novel Botulinum toxin topical gel for the treatment of lateral canthal lines. J Dermatol Surg 2010;36:211–18.